Latest Protease inhibitors Stories
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1), TURQUOISE-I, using VIEKIRA PAK with ribavirin (RBV), demonstrated sustained
JERUSALEM, February 19, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, N.J., Jan.
DALLAS, January 23, 2015 /PRNewswire/ -- LifeScienceIndustryResearch.com adds Hepatitis C Global Clinical Trials Review, H2, 2014 as well as Hepatitis C Market & Forecast,
CORK, Ireland, December 29, 2014 /PRNewswire/ -- -- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed
-- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients -- In Phase 3 clinical trials, HOLKIRA
- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure NORTH CHICAGO, Ill., Dec.
SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc.
GENEVA, December 1, 2014 /PRNewswire/ -- Licence will support the work of the recently launched Paediatric HIV Treatment Initiative (PHTI) to Develop Better Adapted